TMDX Stock Forecast & Price Target

TransMedics Group is viewed constructively because the core liver franchise is still gaining share while transplant volumes recover, and management expects 2026 to finish with higher OCS Liver share than in 2025 despite a noisy competitive backdrop. The bigger fundamental driver is a likely 2027 inflection, as ENHANCE Part B, DENOVO, CHOPS, OCS Kidney and Italy/OUS expansion begin adding incremental revenue against a cost base already built in 2026, which should improve operating leverage. With 2Q26 revenue estimated at $195M versus $183M consensus, flights up 20% in May and over 30% in June-to-date, and 2026 revenue around $749M potentially above guidance, the setup supports further upside.

TransMedics Group is facing a weakening fundamental setup because delayed clinical programs in 2026 forced accelerated CHOPS development and lifted spending without the expected revenue contribution, while additional regulatory clearances remain uncertain. Its outlook is further pressured by a concentrated customer base, no specific U.S. reimbursement code for OCS, and rising competitive risk as OrganOx is expected to outgrow TMDX in fiscal year 2026; the company also risks share loss and pricing pressure as market acceptance of its novel platform remains unproven. Financially, 1Q26 adjusted operating expenses were $83 million, GAAP gross margin fell in Product by 400 bps and in Service by 300 bps, and revenue could be challenged if 2026 growth trends slow toward the cited $738 million downside scenario.